Sensible Biotechnologies is developing the first cell-based platform for the design, optimisation and manufacturing of mRNA therapeutics, engineering host cells to produce long, pure, low-immunogenicity transcripts without enzyme-heavy in vitro transcription. Founded in 2021 and part of Y Combinator's Summer 2021 batch, it operates from Boston, Oxford and Bratislava, and pairs its biology platform with an AI-guided sequence-design suite built on NVIDIA accelerated computing. Backers include BlueYard Capital, Recode Ventures, Kaya VC, Backed VC, Y Combinator, ZAKA VC and Onsight.
1
Round
1
Industry
4
Tags
Sep 2, 2026
Latest raise
Funding activity · 1 round
Sep 2, 2026
$13.5M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
